Immunophenotypic and molecular cytogenetic features of the cell line UP-LN1 established from a lymph node metastasis of a poorly-differentiated carcinoma

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 683-691

  Chang, Cherry Tzu Ru ^a   Weng, Wen Hui ^b   Chou, Andy Shau Bin ^a,c,d   Chuang, Cheng Keng ^c   Porwit McDonald, Anja ^b   Pang, See Tong ^c   Larsson, Catharina ^b   Liao, Shuen Kuei ^a,c  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Cell line; CGH; Lymph node; Metastasis; Poorly differentiated carcinoma; SKY

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; CYTOKERATIN 20; CYTOKERATIN 7; CYTOKERATIN AE1; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL STRAIN UP LN1; CELL STRUCTURE; CHROMOSOME 19; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOGENETICS; EPITHELIUM CELL; FEMALE; FLOW CYTOMETRY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; KARYOTYPING; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR BIOPSY; TUMOR CELL LINE; TUMOR DIFFERENTIATION; TUMOR GROWTH;

AGED; ANIMALS; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA, NEOPLASM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; SPECTRAL KARYOTYPING; TRANSPLANTATION, HETEROLOGOUS;

EID: 17444426125     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Lewko WM, Ladd P, Hubbard WJ, He YJ, Vaghmar R, Husseini S, Chang L, Moore M, Thurman G and Oldham OK: Tumor acquisition, propagation and cryopreservation. The culture of human colorectal cancer. Cancer 64: 1600-1607, 1989.
2. Liao S-K, Perng Y-P, Shen Y-C, Chung P-J, Chang Y-S and Wang C-H: Chromosomal abnormalities of a new nasopharyngeal carcinoma cell line (NPC-BM1) derived from a bone marrow metastatic lesion. Cancer Genet Cytogenet 103: 53-58, 1998.
3. Ji J, Chen X, Leung SY, Chi J-TA, Chu KM, Yuen ST, Li R, Chan ASYY, Li J, Dunphy N and So S: Comprehensive analysis of gene expression profiles in human gastric cancer cell lines. Oncogenes 21: 6549-6556, 2002.
4. Mori M, Mimori K, Yoshikakawa Y, Shibuta K Utsunomiya T, Sadanaga N, Tanaka F, Mastuyama A, Inoue H and Sugimachi S: Analysis of the gene-expression profile regarding the progression of human gastric carcinoma. Surgery 131: S39-47, 2002.
5. Cheung Y-C, Wan YL, Lui Y-L and Lee K-F: Sonographically guided core-needle biopsy in the diagnosis of superficial lymphadenopathy. J Clin Ultrasound 28: 283-289, 2000.
6. Varma M, Berney DM, Jasani B and Rhodes A: Technical variations in prostatic immunohistochemistry: need for standardization and stringent quality assurance in PSA and PSAP immunostaining. J Clin Pathol 57: 687-690, 2004.
7. Prieto VG, Lugo J and McNutt NS: Intermediate- and low-molecular-weight keratin detection with the monoclonal antibody MNF116. An immunohistochemical study on 232 paraffin-embedded cutaneous lesions. J Cut Pathol 23: 234-241, 1996.
8. Attia MA and Weiss DW: Immunology of spontaneous mammary carcinoma in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res 26: 1787-1800, 1966.
9. Liao S-K, Perng Y-P, Lee L-A, Chang KSS, Lai G-M, Wang H and Ho Y-S: Newly established MST-1 tumor cell line and tumor-infiltrating lymphocyte culture from a patient with soft tissue melanoma (clear cell sarcoma) and their potential applications to patient immunotherapy. Eur J Cancer 32A: 346-356, 1998.
10. Steplewski Z, Blaszczyk-Thurin M, Lubeck M, Loibner H, Scholtz D and Koprowski H: Oligosaccharide Y specific monoclonal antibody and its isotype switch variants. Hybridoma 91: 201-210, 1990.
11. Liao S-K: Laboratory evaluation of a mouse-human chimeric antibody (XO-3) for hepatocellular carcinoma. Proc Int Conf Adv Technol 11: 94-101, 1995.
12. Longenecker BM, Rahman AFR, Barrington-Leigh J, Leighj DUB, Purser AR, Greenberg AH, Williams DJ, Keller O, Petrik PK, Thay TY and Suresh MR: Monoclonal antibody against a cryptic carbohydrate antigen of murine and human lymphocytes. I. Antigen expression in non-cryptic or unsubstituted form on certain murine lymphomas, on a spontaneous murine mammary carcinoma, and on several human adenocarcinomas. Int J Cancer 33: 123-129, 1984.
13. Chuang C-K, Shen Y-C, Wu J-H, Tsai L-H and Liao S-K: Immunobiologic, cytogenetic and drug response features of a newly established cell line (SCRC-1) from renal small cell carcinoma. J Urol 163: 1016-1021, 2000.
14. Lin WC, Yasumura S, Suminami Y, Sung MW, Nagshima S, Stanson J and Whiteside TL: Constitutive production of IL-2 by human carcinoma cells, expression of IL-2 receptor, and the tumor cell growth. J Immunol 133: 4805-4816, 1995.
15. Mitelman F: An International System for Human Cytogenetic Nomenclature. Basel: S. Karger, pp 30-73, 1995.
16. Sutherland RM: Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240: 177-184, 1988.
17. Chuang C-K and Liao S-K: Human bladder carcinoma cells with an unusual pattern of in vitro growth: transition from nonproliferative spheroids to active monolayer growth upon interaction with tumor-derived fibroblasts. Anticancer Res 20: 749-760, 2000.
18. Wang NP, Zee S, Zarbo RJ, Bacci CE and Gown AM: Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl Immunochem 3: 99-107, 1995.
19. Blumenfeld W, Turi GK, Harrison G, Latuszynski D and Zhang C: Utility of cytokeratin 7 and 20 subset analysis as an aid in the identification of primary site of origin of malignancy in cytologic specimens. Diag Cytopathol 20: 63-66, 1999.
20. Chu P, Wu E and Weiss LM: Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 13: 967-972, 2000.
21. Stahel RA, Lacroix H, Sculier JP, Morant R, Richner J, Janzek E, Loibner H and Blythman H: Phase I/II study of monoclonal antibody against Lewis Y hepten in relapsed small-cell lung cancer. Ann Oncol 3: 319-320, 1992.
22. Dettke M and Loibner H: Different types of Fc gamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro. Br J Cancer 82: 441-445, 2000.
23. MacLean GD, Reddish M, Koganty RR, Wong T, Gandhi S, Samuel J, Nabholtz JM and Longenecker BM: Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 36: 215-222, 1993.
24. Möller P and Hammerling GJ: The role of surface HLA-A,B,C molecules in tumor immunity. Cancer Surv 13: 101-127, 1992.
25. Anichini A, Mortariani R, Supino R and Parmini G: Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype. Int J Cancer 46: 508-515, 1990.
26. Perng Y-P, Lin C-C, Perng I-M, Shen Y-C, Chuang C-K and Liao S-K: Culture medium induces morphological changes of melanoma cells associated with change in sensitivity to lysis by lymphokine-activated killer cells. Cancer Biother Radioparmaceut 12: 317-331, 1997.
27. Tsao S-W, Wang X, Liu Y, Cheung YC, Feng H, Zhong Z, Wong N, Yuen PW, Lo AKF and Huang DH: Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochem Biophys Acta 1590: 150-158, 2002.
28. Vlerninckx K, Vakaet L Jr, Marel M, Fiers W and Van Rey F: Genetic manipulation of E-cadherin expression by epithelial cells reveals an invasion suppressor role. Cell 66: 107-119, 1991.
29. Frixen UH, Behrens J, Schs M, Eberle G, Voss B, Warde A, Lorothea D and Birchmeier W: E-cadherin-mediated cell-cell adhesions prevent invasiveness of human carcinoma cells. J Cell Biol 113: 173-185, 1991.
30. Shimoyama Y, Nagafuchi A, Fujita S, Gotoh M, Takeichi M, Tsukita S and Hirohashi S: Cadherin dysfunction in a human cancer cell line: possible involvement of loss of α-catenin expression in reduced cell-cell adhesiveness. Cancer Res 52: 5770-5774, 1992.
31. Kase S, Sugio K, Yamazaki, Okamoto, Yano T and Sugimach K: Expression of E-cadherin and β-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 6: 4789-4796, 2000.
32. Zamora PO, Danielson KG and Hosick KL: Invasion of endothelial cell monolayers on collagen gels by cells from mammary tumor spheroids. Cancer Res 440: 4631-4639, 1980.
33. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH and Galle PR: Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells. A mechanism of immune evasion? Nature Med 2: 1361-1366, 1996.
34. Rao PH, Cigudosa JC, Ning Y, Calasanz MJ, Iida S, Tagawa S, Michaeli J, Klein B. Dalla-Favera R, S.C Jhanwar SC, Ried T and Chaganti RSK: Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood 92: 1743-1748, 1998.